Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652600 | 0.84 | ALDH1A1 (0.42) | TSHRPOLBTP53SMN1; SMN2LMNA | |
| SCHEMBL5652348 | 0.82 | TP53 (0.43) | CYP1A2CYP2C9CYP2C19TSHRPOLB | |
| SCHEMBL5650208 | 0.82 | TSHR (0.44) | CYP1A2CYP2C9CYP2C19TSHRPOLB | |
| SCHEMBL5645739 | 0.82 | TP53 (0.43) | CYP1A2CYP2C9CYP2C19TSHRPOLB | |
| SCHEMBL5652526 | 0.78 | TP53 (0.47) | CYP1A2CYP2C9CYP2C19TSHRTP53 | |
| SCHEMBL5650949 | 0.78 | FKBP1A (0.50) | CYP1A2CYP2C9CYP2C19TSHRPOLB | |
| SCHEMBL5645420 | 0.77 | FKBP1A (0.46) | TSHRTP53SMN1; SMN2LMNAHTT | |
| SCHEMBL5650464 | 0.75 | SMN1; SMN2 (0.48) | CYP1A2CYP2C9CYP2C19TSHRPOLB | |
| SCHEMBL5649987 | 0.73 | ALDH1A1 (0.53) | SMN1; SMN2LMNAKDM4EKMT2AALDH1A1 | |
| SCHEMBL5646943 | 0.73 | HPGD (0.45) | TSHRTP53SMN1; SMN2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | claimed |
| US-7279470-B2 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2007-10-09 | — | — | US | disclosed |
| US-7067517-B2 | Use of compounds for decreasing activity of hormone-sensitive lipase | NERO NORDISK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | LIPE, PNLIP, LPL | CYP1A2 1877/4885CYP2C9 2983/4885CYP2C19 1948/4885 |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | LIPE, PNLIP, LPL | CYP1A2 2155/4885CYP2C9 3535/4885CYP2C19 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.